Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 31 July 2006
Lentivector success in avian transgenics
Article reports data that demonstrate Oxford BioMedica's lentiviral vectors can be used to generate transgenic lines with an efficiency of the order of 10 to 100-fold higher than any previous method
Oxford BioMedica announced that a scientific article reporting on its collaboration with Viragen in the field of avian transgenic biomanufacturing is available as an advance online publication of Embo reports (European Molecular Biology Association, McGrew et al, vol 5, no 7) The article, titled "Efficient production of germline transgenic chickens using lentiviral vectors", reports data that demonstrate that Oxford BioMedica's lentiviral vectors can be used to generate transgenic lines with an efficiency of the order of 10 to 100-fold higher than any previously published method
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
Avian transgenic breakthrough reported
Results are first proof-of-principle with an avian-expressed version of interferon beta; it is expected that the Ova system will be capable of cost-effectively expressing many therapeutic proteins
In collaboration with Roslin Institute and Oxford Biomedica, Viragen aims to develop this technology for the efficient, large-scale and cost-effective manufacturing of pharmaceutical protein-based drugs in the eggs laid by flocks of transgenic chickens.
Project leader, Roslin Institute's Helen Sang, commented, "Our results to date are very encouraging.
"The efficiency is such that transgenic lines of chickens can be established with ease, and studies measuring expression of the transgene suggest that predictable levels of expression will be obtained.
"In order to achieve our goal of producing therapeutic proteins in hens' eggs, we must accomplish tissue specific expression of the transgene in the oviduct - a goal we are diligently working toward." Commenting on the results, Oxford BioMedica's chief executive officer, Alan Kingsman said "This is an interesting project and we are delighted to see the LentiVectors having a significant impact in yet another area of commercial biology".
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
